Evidence map›Paper›PMID 34261494›Full record

ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2021

Assessment of intramyocardial hemorrhage with dark-blood T2*-weighted cardiovascular magnetic resonance.

Xingmin Guan, Yinyin Chen, Hsin-Jung Yang, Xinheng Zhang, Daoyuan Ren, Jane Sykes, John Butler, Hui Han, Mengsu Zeng, Frank S Prato and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05604131 (Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05604131 phase2recruitingnot on this mapstarted 2022, after this paper: background citation

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

TypeinterventionalSponsorRohan DharmakumarRan2022 to 2029Enrolled89ConditionsAcute Myocardial Infarction Type 1ArmsDeferiprone Tablets, Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Xingmin GuanDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Biomedical Imaging Research Institute, PACT Bldg - Suite 400, 8700 Beverly Blvd, Los Angeles, CA, USA.
Yinyin ChenDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Biomedical Imaging Research Institute, PACT Bldg - Suite 400, 8700 Beverly Blvd, Los Angeles, CA, USA.
Hsin-Jung YangDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Biomedical Imaging Research Institute, PACT Bldg - Suite 400, 8700 Beverly Blvd, Los Angeles, CA, USA.
Xinheng ZhangDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Biomedical Imaging Research Institute, PACT Bldg - Suite 400, 8700 Beverly Blvd, Los Angeles, CA, USA.
Daoyuan RenDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jane SykesLawson Health Research Institute, University of Western Ontario, London, ON, Canada.
John ButlerLawson Health Research Institute, University of Western Ontario, London, ON, Canada.
Hui HanDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Biomedical Imaging Research Institute, PACT Bldg - Suite 400, 8700 Beverly Blvd, Los Angeles, CA, USA.
Mengsu ZengDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Frank S PratoLawson Health Research Institute, University of Western Ontario, London, ON, Canada.
Rohan DharmakumarDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Biomedical Imaging Research Institute, PACT Bldg - Suite 400, 8700 Beverly Blvd, Los Angeles, CA, USA. rohandkumar@csmc.edu.ORCID 0000-0003-4120-4635
Cedars-Sinai Medical Center · USWestern University · CASun Yat-sen University · CN

Funding

Developing a MRI-guided Disease-Modifying Therapy for Post Infarction Chronic Heart FailureR01HL133407 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI Rohan Dharmakumar · 2017 to 2026
$4.9M
An Accurate Non-Contrast-Enhanced Cardiac MRI Method for Imaging Chronic Myocardial Infarctions: Technical Developments to Rapid Clinical ValidationR01HL136578 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI LI, DEBIAO · 2017 to 2020
$3.4M
Mechanistic Insights to A Translatable Therapy for Acute Reperfused Hemorrhagic Myocardial InfarctionsR01HL147133 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI DHARMAKUMAR, ROHAN, FRANCIS, JOSEPH · 2020 to 2023
$3.2M
NHLBI NIH HHS R01 HL133407NHLBI NIH HHS R01 HL136578NHLBI NIH HHS R01 HL147133
6 · The paper itself

Abstract

backgroundIntramyocardial hemorrhage (IMH) within myocardial infarction (MI) is associated with major adverse cardiovascular events. Bright-blood T2*-based cardiovascular magnetic resonance (CMR) has emerged as the reference standard for non-invasive IMH detection. Despite this, the dark-blood T2*-based CMR is becoming interchangeably used with bright-blood T2*-weighted CMR in both clinical and preclinical settings for IMH detection. To date however, the relative merits of dark-blood T2*-weighted with respect to bright-blood T2*-weighted CMR for IMH characterization has not been studied. We investigated the diagnostic capacity of dark-blood T2*-weighted CMR against bright-blood T2*-weighted CMR for IMH characterization in clinical and preclinical settings. MATERIALS AND

methodsHemorrhagic MI patients (n = 20) and canines (n = 11) were imaged in the acute and chronic phases at 1.5 and 3 T with dark- and bright-blood T2*-weighted CMR. Imaging characteristics (Relative signal-to-noise (SNR), Relative contrast-to-noise (CNR), IMH Extent) and diagnostic performance (sensitivity, specificity, accuracy, area-under-the-curve, and inter-observer variability) of dark-blood T2*-weighted CMR for IMH characterization were assessed relative to bright-blood T2*-weighted CMR.

resultsAt both clinical and preclinical settings, compared to bright-blood T2*-weighted CMR, dark-blood T2*-weighted images had significantly lower SNR, CNR and reduced IMH extent (all p < 0.05). Dark-blood T2*-weighted CMR also demonstrated weaker sensitivity, specificity, accuracy, and inter-observer variability compared to bright-blood T2*-weighted CMR (all p < 0.05). These observations were consistent across infarct age and imaging field strengths.

conclusionWhile IMH can be visible on dark-blood T2*-weighted CMR, the overall conspicuity of IMH is significantly reduced compared to that observed in bright-blood T2*-weighted images, across infarct age in clinical and preclinical settings at 1.5 and 3 T. Hence, bright-blood T2*-weighted CMR would be preferable for clinical use since dark-blood T2*-weighted CMR carries the potential to misclassify hemorrhagic MIs as non-hemorrhagic MIs.

Indexed as

HemorrhageMyocardial InfarctionAnimalsDogsHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMyocardiumPredictive Value of TestsBright-blood T2*Dark-blood T2*Intramyocardial hemorrhageT2* MRI

Identifiers

PMID34261494
PMCPMC8281666
OpenAlexW3182314838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.